Use of Combination Regimens in Frontline RCC

Author(s):

Martin H. Voss, MD, presents data supporting the use of various combination regimens in the frontline treatment of renal cell carcinoma (RCC), focusing on the pivotal trials such as CheckMate 214, KEYNOTE 426, and the CLEAR trial, emphasizing their respective efficacy, safety, and overall impact on the current treatment landscape for RCC patients.

EP: 1.Evolving Treatment Standards in Non-Clear Cell RCC

EP: 2.Extended Follow Up of KEYNOTE-B61

EP: 3.Ongoing Clinical Trials in the front-line setting of advanced non-clear cell RCC

EP: 4.STELLAR 304: Zanzalintinib plus nivolumab in non-clear cell RCC

EP: 5.Case Presentation: 61-year-old male Renal Cell Carcinoma

Now Viewing

EP: 6.Use of Combination Regimens in Frontline RCC

EP: 7.Treatment Decision Making in first-line combinations for advanced RCC

EP: 8.AE Management for Combination Regimens in Advanced RCC

EP: 9.AE Management for Combination Regimens in Advanced RCC

EP: 10.Optimizing Treatment in Advanced RCC

EP: 11.Dr Albiges Discusses a Non-Clear Cell RCC Patient Profile

EP: 12.Updates in the Treatment Approach for Non-clear cell RCC

EP: 13.Dr Albiges Reviews Long term follow up data from KEYNOTE-B61

EP: 14.Emerging Therapies in the Front-line Setting of Advanced non-clear cell RCC

EP: 15.Biomarker-driven combination treatment approach in non-clear cell RCC (Met-driven)

EP: 16.Summary and Forward Looking for RCC

Please review data supporting the use of other combination regimens in frontline RCC.
- CheckMate 214 (nivo +ipi): Tannir, et al. ASCO GU 2024. Abstract 363
- KEYNOTE 426 (axi +pembro): Plimack ER, et al. Eur Urol. 2023)
- CLEAR (len+pem vs sunitinib): Viktor Grunwald et. al, ASCO 2024, Abstract 4524